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A B S T R A C T
Background
Eye movement disorders may affect over 70% of stroke patients. These eye movement disorders can result in difficulty maintaining
the normal ocular position and difficulty moving the eyes appropriately. The resulting functional disabilities include a loss of depth
perception, reduced hand-to-eye co-ordination, marked difficulties with near tasks and reading and reduced ability to scan the visual
environment. They can also impact on the effectiveness of rehabilitation therapy. There are a wide variety of different treatment
interventions proposed for eye movement disorders after stroke. However, in the past, there has been a lack of evidence specific to the
impact of interventions on the functional outcome of patients with stroke.
Objectives
To determine the effects of interventions for eye movement disorders on functional ability following stroke.
Search strategy
We searched theCochrane StrokeGroupTrialsRegister (February 2011), theCochraneEyes andVisionGroupTrialsRegister (December
2009) and nine electronic bibliographic databases including CENTRAL (The Cochrane Library 2009, Issue 4), MEDLINE (1950 to
December 2009), EMBASE (1980 to December 2009), CINAHL (1982 to December 2009), AMED (1985 to December 2009),
and PsycINFO (1967 to December 2009). We also searched reference lists and trials registers, handsearched journals and conference
proceedings, and contacted experts.
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Selection criteria
Randomised trials in adults after stroke where the intervention was specifically targeted at improving the eye movement disorder or
improving the ability of the participant to cope with the eye movement disorder. The primary outcome was functional ability in
activities of daily living. Secondary outcomes included functional ability in extended activities of daily living, eye movement measures,
balance, falls, depression or anxiety, discharge destination or residence after stroke, quality of life and social isolation, adverse events,
and death.
Data collection and analysis
Two authors independently screened abstracts, extracted data and appraised trials. We undertook assessment of methodological quality
for allocation concealment, blinding of outcome assessor, method of dealing with missing data, and other potential sources of bias.
Main results
Two studies (28 participants but only five were people with stroke) met the inclusion criteria and were included in this review. Both
studies investigated pharmacological interventions for disorders of eye movement in patients with stroke. It was not appropriate to
pool data and we were not able to draw conclusions from these studies. We found no other randomised studies which investigated
interventions for disorders of eye movement in patients with stroke.
Authors’ conclusions
There is insufficient evidence to reach conclusions about the effectiveness of interventions for patients with eye movement disorders
after stroke. High quality research in the form of well-designed randomised trials are urgently required.
P L A I N L A N G U A G E S U M M A R Y
Interventions for eye movement disorders in people with stroke
Eye movement disorders may affect over 70% of stroke patients and can make it difficult to keep both eyes in their normal position
when looking straight ahead, or can make it difficult to move the eyes accurately to look in a different direction. This can affect patients’
perception of depth, makes it difficult for them to take in their whole surroundings and can severely affect the ability to read. We found
only two randomised controlled trials which investigated treatments for eye movement disorders. Both of these studies investigated
the effect of drug treatments. A total of 28 participants were included but only five of these were people with stroke. One study found
that the people with stroke responded differently to the drug treatment than people who had eye movement disorders due to other
conditions. These studies provide too little evidence from which to reach any conclusions about the effectiveness of interventions for
patients with eye movement disorders after stroke. Further research is urgently required.
B A C K G R O U N D
The association between visual impairment and disability in ac-
tivities of daily living is well established (Wolter 2006). The ser-
vices available to patients with visual problems following stroke
are inconsistent at present. We aim to provide an evidence base
to facilitate the development of further research and promote best
treatments for patients with visual problems following stroke.
This review is one of a series of reviews being supported by the
Royal National Institute for the Blind (RNIB). The aim of these
reviews is to identify the evidence base for treatments of visual
problems following stroke. The project team aims to develop ap-
propriate primary research proposals on completion of these re-
views.
Description of the condition
Disorders of eye movements are caused by damage to the extra-
ocular muscle, the cranial nerves supplying the ocular muscles,
or to the neural pathways that control these nerves. It has been
reported that in symptomatic patients up to 86% of those with
stroke or non-traumatic acquired brain injury have eye movement
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disorders (Ciuffreda 2007; Rowe 2009a) and in a general popula-
tion of stroke patients, at various stages of recovery, between 7%
and 55% have eye movement disorders (Clisby 1995; Freeman
1987; MacIntosh 2003). These disorders can cause a variety of
problems (Jones 2006; Pederson 1981; Rowe 2009a) including
the following difficulties and eye movements.
Difficulties in maintaining the normal ocular position
• Conjugate eye deviation: both eyes turn constantly to one
side.
• Strabismus: one eye deviates horizontally or vertically, or
both, with or without the eye rotating away from the straight
position so the eyes are no longer aligned.
• Nystagmus: frequent involuntary oscillations and other
random eye movements.
Difficulty with moving eyes appropriately
• Saccades: fast movements that carry the eye from one target
to another.
• Pursuits: slow movements that allow a moving object to be
followed.
• Fixation: ability to maintain steady eye position on a target.
• Convergence: ability of the eyes to turn in to focus on near
objects.
• Divergence: ability of the eyes to turn out and focus on
distant objects.
• Vestibulo-ocular reflex: movement of the eyes in response to
a quick head movement.
• Palsy: inability to use one or more of the muscles that move
the eye up, down, left or right.
The result is a range of functional disabilities. These include a
loss of depth perception, reduced hand-to-eye co-ordination and
marked difficulties with near tasks and reading (MacIntosh 2003).
Reduced ability to scan the visual environment may affect visual
memory, recognition, the ability to formulate plans and decision
making (Wolter 2006). The disorders may also impact on the
effectiveness of rehabilitation therapy in regaining mobility and
activities of daily living (MacIntosh 2003), and have an impact on
quality of life (Ciuffreda 2008).
Description of the intervention
There are a number of different treatment and management ap-
proaches available to patients with eye movement disorders. This
review considers any intervention that is specifically targeted at
improving the disorder, or improving the ability of the patient to
cope with it.
Treatments for eyemovement disorders can be described as restitu-
tion, compensation or substitution (Kerkhoff 2000). In addition
to these types of treatments, this review will also consider assess-
ment and screening interventions that are specifically targeted at
patients with eye movement disorders.
These interventions may include, but not be limited to, the fol-
lowing.
• Restitutive interventions: convergence training, pursuit
training, saccade training.
• Compensative interventions: training eye movements for
reading, compensatory head posture or movements, use of eye
blinks or colour cues, training in activities of daily living.
• Substitutive interventions: prisms, eye patches, injections
and surgery, magnification, environmental modification.
• Assessment and screening interventions: standardised visual
assessment, screening and referral for visual assessment and
intervention, assessment of different types of eye movement.
How the intervention might work
Restitution
Restitution includes the biochemical events that help restore func-
tional neural tissue: the reduction of oedema, absorption of blood,
restoration of normal neuronal physiology and restoration of axon
transport. In the past it has been thought that restitutive ap-
proaches would have limited effect in visual rehabilitation. How-
ever, treatments of convergent fusion and stereopsis through rep-
etition training of the deficient function have been reported as
effective (Kerkhoff 2000). Restitutive interventions include those
where there is direct training of the impaired function or repetitive
stimulation of eye movement.
Compensation
Compensation aims to improve the mismatch between the pa-
tients’ skills and the demands placed on them by their environ-
ment by teaching them to compensate using a spared or intact
function (Kerkhoff 1999; Kerkhoff 2000).
Substitution
Substitution involves adaptation of visual components that have
been lost or disrupted through the use of optic devices or environ-
mental modifications (Kerkhoff 1999; Kerkhoff 2000).
Assessment and screening interventions
These may work by ensuring that the eye movement disorder is
appropriately diagnosed, which enables other interventions to be
prescribed or enables patients to be given advice and education
about the management of their condition and adaptation of their
environment.
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The interventions for eye movement disorders are therefore pro-
posed to work by either restoring the eye movement (restitution);
compensating for the eye movement disorder by changing be-
haviour or activity (compensation); substituting for the eye move-
ment disorder by using a device or extraneous modification (sub-
stitution); or ensuring appropriate diagnosis, referral and treat-
ment prescription through standardised assessment or screening,
or both.
Why it is important to do this review
Eye movement disorders are relatively common after stroke. They
can result in wide-ranging functional difficulties (Rowe 2009a;
Rowe 2009b) and may negatively impact on rehabilitation after
stroke. There are a wide variety of different treatment interven-
tions proposed for eye movement disorders after stroke. The body
of evidence relating to eye movement disorders is growing. How-
ever, in the past, there has been a lack of evidence specific to the
impact of interventions on the functional outcome of patients
with stroke (Ciuffreda 2008). There are two recent published re-
views of the literature relating to visual problems following stroke
(Jones 2006; Wolter 2006). Both of these reviews provide a broad
overview of the literature relating to visual problems after stroke
but do not provide a rigorous, systematic analysis of outcomes of
treatment interventions for eye movement disorders. Two reviews
(Barrett 2009; Riggs 2007) were completed but with a number of
methodological limitations. Neither review identified primary ev-
idence relating to eye movement disorders in patients with stroke.
A high-quality systematic review of the existing evidence base is
essential in order to determine the evidence for the effectiveness
of any treatment or management approaches for stroke patients
with eye movement disorders. This review will also facilitate ap-
propriate planning and prioritisation of future primary research.
O B J E C T I V E S
Research question
Do interventions for eye movement disorders improve functional
ability following stroke?
Specific objectives
1. To determine whether, in patients with eye movement
disorders following stroke:
i) restitutive interventions are more effective than
control, placebo or no intervention at improving functional
ability in activities of daily living;
ii) compensative interventions are more effective than
control, placebo or no intervention at improving functional
ability in activities of daily living;
iii) substitutive interventions are more effective than
control, placebo or no intervention at improving functional
ability in activities of daily living;
iv) assessment and screening interventions are more
effective than standard care at improving functional ability in
activities of daily living.
2. To determine whether, in patients with eye movement
disorders following stroke:
i) restitutive interventions are more effective than
control, placebo or no intervention at improving secondary
outcomes;
ii) compensative interventions are more effective than
control, placebo or no intervention at improving secondary
outcomes;
iii) substitutive interventions are more effective than
control, placebo or no intervention at improving secondary
outcomes;
iv) assessment and screening interventions are more
effective than standard care at improving secondary outcomes.
3. To explore the relationship between patient characteristics
and the effect of interventions aimed at improving functional
abilities in activities of daily living by using subgroup analysis.
4. To make specific recommendations for future research into
the effectiveness of interventions for eye movement disorders
based on a knowledge of the existing evidence base.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and randomised controlled
cross-over trials (analysing the first phase as a parallel group trial).
Types of participants
Adult participants (over 18 years of age) after stroke (using the
WorldHealthOrganization (WHO) definition of stroke, or a clin-
ical definition if not specifically stated, that is, signs and symp-
toms persisted longer than 24 hours) and with a clinical diagnosis
of an eye movement disorder. The eye movement disorder must
have occurred as a direct result of the stroke. We accepted studies
that included participants based on symptoms which can be as-
sumed to be present as a direct result of an eyemovement disorder.
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These symptoms include double vision, difficulty reading, blurred
vision, wobbling vision, and excessive head movements.
We documented the type of eye movement disorder and planned
to conduct subgroup analysis to investigate the effect of each type.
If possible, we documented the type of eyemovement disorder (III,
IV, and VI nerve palsy; reduced fixation or gaze holding; saccadic
palsy or problems; smooth pursuit palsy or problems; strabismus;
nystagmus; reduced convergence; conjugate deviation; skew devi-
ation), the deviation of eye movement (horizontal, vertical, tor-
sional), and the severity of eye movement disorder (slight, small,
moderate, marked; paralysis or paresis; monocular or binocular)
and planned to investigate the effects via further subgroup analy-
ses.
Types of interventions
We included any intervention that was specifically targeted at im-
proving the defects of eye movement or improving the ability of
the patient to cope with the disorder. We planned to classify in-
terventions as either restitution, compensation, substitution, or
assessment and screening.
We compared interventions with a no treatment, placebo or a
control intervention, or against standard care. We planned four
specific comparisons: (1) restitutive interventions versus no treat-
ment, placeboor control; (2) compensative interventions versus no
treatment, placebo or control; (3) substitutive interventions versus
no treatment, placebo or control; and (4) assessment and screen-
ing interventions versus standard care.We identified an additional
comparison following the selection of included trials: (5) pharma-
cological interventions versus no treatment, placebo or control.
We documented a description of the placebo or control interven-
tion, or standard care. We accept as standard care any ’normal’,
’routine’ or ’usual’ care as defined by the researchers.
Types of outcome measures
If possible, we assessed the outcome at the end of the intervention
period and at a follow-up point (ideally six months after the com-
pletion of the intervention).
Primary outcomes
Functional ability in activities of daily living
We included studies using the following validated scales: Barthel
Activities of Daily Living Index (Mahoney 1965), Functional
Independence Measure (FIM) (Smith 1990), Modified Rankin
Scale, Katz Index of Activities of Daily Living (Katz 1963), and
the Rehabilitation Activities Profile. If a study reported more than
one of these functional ability scales, we used the scale listed ear-
liest in this list.
Secondary outcomes
Functional ability in extended activities of daily living
Nottingham Extended Activities of Daily Living scale, Lawton
Instrumental Activities of Daily Living, Frenchay Activities Index
(Holbrook 1983), Rivermead ADL score.
Eye movement
From orthoptic tests, including size of deviation, gradation of
movements, severity of disorder (slight, small, moderate, marked;
paralysis or paresis; monocular or binocular).
Balance
Berg Balance Scale (Berg 1989), Functional Reach (Duncan
1990), Get Up and Go Test (Mathias 1986), Standing Balance
Test, Step Test or other standardised balance measure. We did not
include measures of weight distribution or postural sway during
standing as it was not possible for us to establish the relationship
between the ability to maintain balance and these outcomes.
Falls
Number of reported falls, Falls Efficacy Scale (Tinetti 1990).
Depression and anxiety
Hospital Anxiety and Depression Scale, Beck Depressive Inven-
tory, General Health Questionnaire, Geriatric Depression Scale.
Discharge destination or residence after stroke
Dichotomous variable: discharged to previous place of residence
(that is, place of residence prior to stroke) or discharged to alter-
native destination.
Quality of life and social isolation
EQ5D, Health-Related Quality of Life Scale, Quality of Well-
Being Scale, Short Form 36.
Adverse events
Any reported adverse events, excluding falls and death.
Death
Search methods for identification of studies
See the ’Specialised register’ section in theCochrane Stroke Group
module.
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Electronic searches
We searched the Cochrane Stroke Group Trials Register (Febru-
ary 2011), the Cochrane Eyes and Vision Group Trials Regis-
ter (December 2009), and the following electronic bibliographic
databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2009, Issue 3 at
www.thecochranelibrary.com (Appendix 1);
• MEDLINE (1950 to December 2009) (Appendix 2);
• EMBASE (1980 to December 2009) (Appendix 3);
• CINAHL (1982 toDecember 2009) (Appendix 4);
• AMED (1985 to December 2009) (Appendix 5);
• PsycINFO (1967 to December 2009) (Appendix 6);
• Dissertations & Theses (PQDT) database (1861 to
December 2009);
• British Nursing Index (1985 to December 2009);
• PsycBITE (Psychological Database for Brain Impairment
Treatment Efficacy) at www.psycbite.com (December 2009).
Searching other resources
In an effort to identify further published, unpublished and ongo-
ing trials, we undertook the following.
1. Searched the following registers of ongoing trials:
i) ClinicalTrials.gov (http://clinicaltrials.gov/); (February
2010);
ii) Current Controlled Trials (www.controlled-trials.com)
(February 2010);
iii) Trials Central (www.trialscentral.org) (February 2010);
iv) Stroke Trials Registry (www.strokecenter.org/trials/)
(February 2010);
v) Health Service Research Projects in Progress (
wwwcf.nlm.nih.gov/hsr_project/home_proj.cfm) (February
2010);
vi) National Eye Institute Clinical Studies Database (
http://clinicalstudies.info.nih.gov/cgi/protinstitute.cgi?
NEI.0.html) (February 2010).
2. Handsearched the following journals and conference
proceedings:
i) British Orthoptic Journal (1939 to 2003);
ii) British and Irish Orthoptic Journal (2004 to 2010);
iii) Australian Orthoptic Journal (1959 to 2010);
iv) Proceedings of the European Strabismological Association
(ESA) (1969 to 2009);
v) International Strabismological Association (ISA)
(1966 to 2010);
vi) International Orthoptic Association (IOA) (
www.liverpool.ac.uk/orthoptics/research/search.htm) (1967 to
2008);
vii) Proceedings of Association for Research in Vision and
Ophthalmology (www.arvo.org) (1969 to 2010).
3. Searched the references supplied by commercial companies
providing interventions aimed at restoration of eye movements.
4. Performed citation tracking using Web of Science Cited
Reference Search for all included studies.
5. Searched the reference lists of included trials and review
articles about vision after stroke.
6. Contacted experts in the field (including authors of
included trials and excluded studies identified as possible
preliminary or pilot work).
We searched for trials in all languages and arranged for translation
of trials published in languages other than English.
Data collection and analysis
One review author (CH) ran all the electronic searches, down-
loaded references into bibliographic software, and removed dupli-
cates. One review author (CH) excluded any titles which were ob-
viously not related to stroke and vision. We obtained the abstracts
for any references related to stroke and vision. Two review au-
thors (CH, AP) independently considered each of these abstracts,
excluded any studies which were clearly not RCTs or cross-over
trials, and excluded any studies where the intervention was not
specifically aimed at improving the eye movement disorder or the
patient’s ability to cope with the eye movement disorder. We re-
solved any disagreements through discussion. We obtained the full
papers for any studies included at this stage.
Selection of studies
Two review authors (CH, AP) independently applied the selection
criteria, considering and documenting the type of studies, type of
participants, intervention, comparison intervention, and the out-
comemeasures. Each review author classified each study as include
or exclude. If there was disagreement between these two review
authors, they reached consensus through discussion involving a
third review author.
We listed any excluded studies that included participants with
eye movement disorders in the Characteristics of excluded studies
table, with the reason for exclusion. We did not list in the
Characteristics of excluded studies table studies that were excluded
because they included participants that did not have eye move-
ment disorders (that is, visual neglect, age-related visual problems,
or visual field loss) unless the two review authors agreed that there
was a clear reason to do so.
Data extraction and management
We used a pre-designed data extraction form to record data from
the included studies. Two review authors (CH, AP) independently
documented the following.
• Methods: study design, method of randomisation.
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• Participants: number of participants, inclusion criteria. We
documented the method of diagnosing the eye movement
disorder. We recorded the country of origin of participants.
• Interventions: description of interventions given to each
treatment group including, if relevant, the duration, intensity,
frequency, or dose. We classified the type of intervention as
restitution, compensation, substitution, or assessment and
screening, and the type of control as no treatment, placebo,
control, or standard care. We documented the professional
background of the person providing the intervention (e.g.
occupational therapist, orthoptist).
• Outcomes: we documented the primary and secondary
outcomes relevant to this review. If a study used a number of
different methods of measuring the same outcome, we noted the
outcome to be used for any subsequent analysis.
• Notes: we recorded any important confounding variables. If
a study included more than two intervention groups, we also
recorded the method of including these groups in any
subsequent analysis.
In addition, the review authors independently documented, if data
allowed, the following demographics of the included participants:
age, gender, place of residence, type of stroke, side of stroke, time
since stroke, initial eye movement disorders, and initial functional
ability.
If there were any discrepancies between data extracted by the two
review authors, these were resolved through discussion.
Assessment of risk of bias in included studies
We assessed risk of bias by answering the following questions for
each included study, and documenting this within the ’Risk of
bias’ tables.
Was allocation adequately concealed?
Studies with adequate concealment included those which used
central randomisation at a site remote from the study, comput-
erised allocation in which records were in a locked readable file
accessible only after entering patient details, or the drawing of
opaque envelopes. Studies with inadequate concealment included
those using an open list or a table of random numbers, open com-
puter systems, or the drawing of non-opaque envelopes. Studies
with unclear concealment included those with no or inadequate
information in the report.
Was knowledge of the allocated intervention adequately
concealed from the outcome assessor?
We considered studies to be adequately concealed if the outcome
assessor was masked and the report did not identify any unmask-
ing. We considered studies inadequately concealed if the outcome
assessor was not masked or where the report clearly identified that
unmasking occurred during the study. We documented conceal-
ment as unclear if a study did not state whether or not an outcome
assessor was masked or there was insufficient information to judge.
Were incomplete outcome data adequately addressed?
Studies that adequately addressed incomplete outcome data had:
no missing outcome data; missing outcome data which were un-
likely to be related to a true outcome; missing outcome data which
were balanced in numbers across intervention groups, with similar
reasons for missing data across the groups; a reported effect size
(difference in means or standardised difference in means) among
missing outcomes which were not enough to have a clinically rel-
evant impact on observed effect size; or missing data which had
been imputed using appropriate methods. Studies which inade-
quately addressed incomplete outcome data had: missing outcome
data which were likely to be related to a true outcome, with either
an imbalance in numbers or reasons for missing data across inter-
vention groups; a reported effect size (difference in means or stan-
dardised difference in means) among missing outcomes enough to
induce clinically relevant bias in observed effect size; or as-treated
analysis done with substantial departure of the intervention re-
ceived from that assigned at randomisation. We documented the
addressing of incomplete outcome data as unclear if there was in-
sufficient reporting to allow this to be assessed, or if this was not
addressed in the report.
Was the study apparently free of other problems that could
put it at a high risk of bias?
We assessed a study not to be free of bias if it was assessed to have
at least one important risk of bias, such as a potential source of bias
related to the specific study design used; an extreme baseline im-
balance; a claim to have been fraudulent; or some other problem.
If there was insufficient information, or the information provided
was unclear, we documented the risk of other bias as unclear.
We produced a ’Risk of bias’ summary figure to illustrate the po-
tential biases within each of the included studies.
Measures of treatment effect
We planned to use Review Manager 5 (RevMan 2011) to carry
out statistical analyses to determine the treatment effect of:
1. restitutive interventions (compared with no treatment,
control, placebo, or standard care);
2. compensative interventions (compared with no treatment,
control, placebo, or standard care);
3. substitutive interventions (compared with no treatment,
control, placebo, or standard care);
4. assessment and screening interventions (compared with
standard care).
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We planned to use a random-effects model for all statistical anal-
yses. For dichotomous variables we planned to calculate the treat-
ment effect using a fixed-effect model and report it as a Peto odds
ratio (OR) with 95% confidence interval (CI). For continuous
data we planned to calculate the treatment effect using standard-
ised mean differences (SMD) and 95% CI where different studies
used different scales for the assessment of the same outcome, and
using mean differences (MD) and 95% CI where studies all used
the same method of measuring the outcome.
Unit of analysis issues
The primary outcome of functional ability in activities of daily
living and secondary outcomes of functional ability in extended
activities of daily living, eyemovement data, balance, falls, depres-
sion and anxiety, and quality of life and social isolation comprise
either ordinal data from measurement scales, count data, or con-
tinuous data. We planned to analyse these as continuous variables.
If reported outcomes had a scale where a lower value is indicative
of a better outcome (for example, a count of the number of falls,
depression and anxiety scales), we multiplied the reported values
by -1 so that in all analyses a higher value would be indicative of
a better outcome.
If studies reported change values these would be included with
follow-up values in the meta-analysis, but we planned sensitivity
analyses to investigate the effect of including these data.
We planned to analyse discharge destination, adverse events, and
death as dichotomous variables.
Dealing with missing data
If an included study did not report a particular outcome, wewould
not include that study in the analyses of that outcome.
If an included study had missing data (for example, it reported
the mean but not standard deviations for the follow-up data) we
would take logical steps to enter an assumed value. Such steps
might include estimating a standard deviation based on a reported
standard error, or estimating a follow-up standard deviation based
on a baseline value. We planned to do sensitivity analyses to in-
vestigate the effect of entering assumed values.
Assessment of heterogeneity
We planned to determine heterogeneity using the I2 statistic. We
would consider I2 > 50% as substantial heterogeneity. If I2 was less
than or equal to 50% we would use a fixed-effect meta-analysis.
If I2 was greater than 50%, we would explore the individual trial
characteristics to identify potential sources of heterogeneity, using
pre-planned subgroup analyses.
Assessment of reporting biases
We attempted to avoid reporting biases by using a comprehensive
search strategy that included searching for unpublished studies
and searching trials registers. We planned to carry out sensitivity
analyses to explore the effect of publication type.
Data synthesis
Two review authors (CH, AP) independently extracted data from
the included trials. One review author (CH) entered the data
into RevMan 5 (RevMan 2011) and the other review author (AP)
checked the entries. They resolved any disagreements through dis-
cussion, with reference to the original report.
Subgroup analysis and investigation of heterogeneity
We intended to explore heterogeneity by subgroup analyses to
investigate the effect of:
• age (under 60 years, 60 years and over);
• gender (male, female);
• time after stroke (less than three months, less than six
months, more than six months, at entry to study);
• type of eye movement disorder (III, IV, VI nerve palsy;
reduced fixation or gaze holding; saccadic palsy or problems;
smooth pursuit palsy or problems; strabismus; nystagmus;
reduced convergence; conjugate deviation; skew deviation);
• deviation of eye movement (horizontal, vertical, torsional);
• severity of eye movement disorder (slight, small, moderate,
marked; paralysis and paresis; monocular and binocular);
• side of stroke (left, right);
• presence of age-related visual problems (presence, absence);
• presence of visual field impairment (presence, absence);
• presence of visual inattention (presence, absence);
• level of motor impairment (mild, moderate, severe);
• level of cognitive impairment (mild, moderate, severe);
• type of treatment (e.g. for compensative interventions:
saccadic eye movement, activities of daily living training; for
substitutive interventions: prisms, patches, environmental
modifications; for assessment and screening: by orthoptist,
occupational therapist, doctor).
We planned to use an established method for subgroup analyses
(Deeks 2001). Prior to future updates of this review we will debate
and reach consensus on the importance of these subgroup anal-
yses, and we will consider reducing the number of planned sub-
group analyses. For future updates we will carry out the planned
subgroup analyses when there are six or more studies included in
a single analysis, all with sufficient information to determine the
subgroups.
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Sensitivity analysis
We intended to carry out sensitivity analysis to explore the effect
of the following methodological features.
• Allocation concealment: we planned to re-analyse data
excluding trials with inadequate or unclear allocation
concealment.
• Masking of outcome assessor: we planned to re-analyse data
excluding trials without or with unclear masking of outcome
assessor.
• Missing outcome data: we planned to re-analyse data
excluding trials with inadequate or unclear methods of dealing
with missing outcome data.
• Other bias: we planned to re-analyse data excluding trials
assessed to have other bias or were unclear as to whether they had
other bias.
• Publication type (peer-reviewed journal, conference abstract
or proceedings, doctoral dissertation): we planned to re-analyse
data including only those trials from peer-reviewed journals.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies; Characteristics of
studies awaiting classification.
Results of the search
Our search strategy identified 7357 titles in the main databases.
After elimination of duplicates and obviously irrelevant studies we
were left with 1034 ’possibly relevant’ abstracts that covered all
topics in this series of reviews: 373 related to visual field loss and
disorders of eye movement. We obtained these 373 abstracts and
two review authors (CC and CH) initially evaluated their inclu-
sion according to the criteria described in the protocol. Where
disagreement arose they sought the opinion of a third review au-
thor (AP). We assessed 81 abstracts as ’include’ or ’unsure’ for the
visual field and eye movement disorders review and we obtained
the full papers for these studies. Review by AP and CH of the full
papers led to the inclusion in this review of two of these 81 studies.
One of the 81 studies had inadequate information on the inclu-
sion criteria and randomisation methods to classify it; contact with
the authors has so far been unsuccessful. It has been added to the
Characteristics of studies awaiting classification table. Where dis-
agreements or uncertainties arose, we held consensus discussions
involving additional authors where required.
One review author (CH) conducted the wider search strategy,
which involved databases of trials, commercial websites, hand-
searching and cited reference searches. The final decision regard-
ing inclusion of prospective studies was decided by discussion
(CH and AP). We did not identify any further trials that could
be included in the review; however, we identified one ongoing
trial via www.clinicaltrials.gov. Two trials had to be investigated
further, from www.clinicaltrials.gov and from the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL). Of these two tri-
als, one was found to be ineligible and the other requires further
clarification before a decision can be made. Their details are in
the Characteristics of excluded studies table and Characteristics of
studies awaiting classification table, respectively.
Thus we identified a total of two studies for inclusion (Leigh
1991; Strupp 2003). In addition, we identified one ongoing study
(Rosner 2010) and two studies which are awaiting assessment (
Hofferberth 1995; Muchnick 1998).
Included studies
Two studies (28 randomised participants, five of whom were par-
ticipants with stroke) met the inclusion criteria for this review
(Leigh 1991; Strupp 2003). Full descriptions of the studies can
be found in the Characteristics of included studies table and in
Table 1 (settings of included studies), Table 2 (demographics of
included participants), and Table 3 (disorders of eye movements).
A brief overview of the studies is presented below.
Study design
Both studies were randomised cross-over trials (Leigh 1991;
Strupp 2003). Both studies provided information on the proce-
dures for randomisation and allocation concealment.
Interventions studied
The interventions studied by both included trials were sys-
temic pharmacological interventions: Leigh 1991 compared tri-
hexyphenidyl (5 mg capsules) with tridihexethyl chloride (25 mg
capsules); Strupp 2003 compared 20 mg 3,4 diaminopyridine
(DAP) plus lactose capsules with lactose-only capsules.
We had not anticipated identifying trials of pharmacological inter-
ventions for eye movement disorders. Systemic pharmacological
interventions were not, therefore, included within the classifica-
tion of interventions (as restitution, compensation, substitution or
assessment and screening interventions) proposed in the protocol.
Following the protocol, review authors (CH, AP) independently
attempted to categorise the systemic pharmacological interven-
tions using the proposed classification system. Disagreement be-
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tween these review authors led to a consensus discussion involving
a further three expert reviewers (PL, BD, FR). Consensus could
not be reached regarding the classification of the systemic phar-
macological interventions using the protocol classification and it
was agreed that an additional classification, pharmacological in-
terventions, should be introduced.
Pharmacological interventions
Both studies investigated the effects of pharmacological interven-
tions. In both of these studies the intervention was systemic drug
treatment for nystagmus. One of the studies (Strupp 2003) com-
pared the effect of a drug with a placebo intervention. The other
(Leigh 1991) planned to compare the effect of the drug with a
placebo. However, the planned placebo intervention was found to
have an active effect on the outcomes measured, so this study was
considered to compare the effect of two different pharmacological
interventions.
Restitutive, compensative, or substitutive interventions
We found no trials investigating the effectiveness of restitutive,
compensative or substitutive interventions.
Assessment and screening interventions
We found no trials investigating the effectiveness of assessment
and screening interventions on relevant outcomes.
Studies included in comparisons within this review
One study (Strupp 2003) compared an active treatment with a
control or placebo treatment. This study included only three par-
ticipants whose eye movement disorder was caused by a stroke.
The results from these patients were reported to be different from
the other patients, which suggests that the response to the inter-
vention in stroke patients may be different to the response of peo-
ple with nystagmus not related to stroke. We chose not to include
these data in a formal comparison as presentation of the results
from this small group could prove misleading.
Populations studied
Both of the studies (Leigh 1991; Strupp 2003) included partici-
pants with nystagmus caused by mixed aetiologies including cere-
bellar atrophy, multiple sclerosis and post-surgical hypoxia. The
percentage of stroke patients was: Leigh 1991, 20%; and Strupp
2003, 18%. Neither study noted the co-existance of any age-re-
lated eye problems, cognitive or motor problems. Both studies ex-
cluded participants with visual inattention, and Leigh 1991 also
excluded participants with visual field loss.
Sample size
The sample sizes were two and three stroke patients in Leigh 1991
and Strupp 2003 respectively.
Outcome measures
Primary outcome
• Functional ability in activities of daily living. Neither of the
included studies used a measure of functional ability.
Secondary outcomes
• Eye movement. Both trials measured aspects of the eye
movements. Strupp 2003 used two-dimensional video-
oculography to record eye movements in horizontal and vertical
directions. Leigh 1991 used the magnetic search coil technique
to measure horizontal and vertical rotations, and an Amsler grid
and video recording to measure eye movement during attempted
fixation in the primary position and at 10 degrees horizontally
and vertically.
• Adverse events. Strupp 2003 assessed adverse events by
asking participants if they experienced side-effects 30 and 60
minutes after the intervention was administered.
Excluded studies
Reasons for the exclusion of studies that were initially thought to
be relevant are provided in the table of Characteristics of excluded
studies. We excluded one study (Repka 1989) because communi-
cation with the study author identified that patients with stroke
were excluded from the study.
Risk of bias in included studies
Assessment of risk of bias for individual studies is described in
the risk of bias tables in Characteristics of included studies and
summarised in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Both studieswere described as randomised double-blind cross-over
trials and were assessed to have adequate allocation concealment.
Blinding
Both studies described that the drugs administered to both treat-
ment groups were identical to look at. Strupp 2003 stated that
masking was maintained until after data analysis was complete.
Leigh 1991 didnot give specific information aboutmasking.How-
ever, since the interventions were administered as identical looking
drugs, the review authors assumed that participants and outcome
assessors were adequately masked to the intervention. Both studies
were, therefore, assessed to have adequate blinding.
Incomplete outcome data
A number of participants dropped out of Leigh 1991 for a variety
of reasons, including adverse events, leading the review authors
assessment that this could be a potential source of bias. One par-
ticipant was excluded from Strupp 2003; the review authors were
uncertain of the impact of this and judged the risk of bias to be
uncertain.
Other potential sources of bias
We judged both Leigh 1991 and Strupp 2003 unlikely to be at risk
of other potential sources of bias. This assessment was based on an
absence of information suggesting bias rather than the presence of
information indicating that the studies were free of bias.
Effects of interventions
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Pharmacological interventions
We found insufficient evidence and data to carry out any analyses
to explore the effect of pharmacological interventions compared
with control or placebo interventions (see Included studies for
details).
Leigh 1991 reported a study that was designed as a placebo
controlled trial comparing the anti-cholinergic ’active’ drug tri-
hexyphenidyl with the ’placebo’ drug tridihexethyl chloride, which
does not cross the blood-brain barrier. The authors report, based
on pooled data from a cross-over study, that trihexyphenidyl was
generally not effective in reducing the velocity of nystagmus. Tri-
hexethyl chloride did have an effect, reducing nystagmus velocity
in four out of six participants, but was associated with side-effects.
Strupp 2003 reported that 3,4-diaminopyridine, a potassium
channel blocker, had a significant effect on nystagmus velocity
compared with a placebo (of lactose). However, this result was not
found in the subgroup of stroke patients.
D I S C U S S I O N
Summary of main results
We found two studieswhich both investigated pharmacological in-
terventions for disorders of eye movement in patients with stroke.
The total number of included stroke patients was five. It was not
appropriate to pool data and we were not able to draw conclu-
sions from these studies. We found no other randomised studies
that investigated interventions for disorders of eye movement in
patients with stroke.
Overall completeness and applicability of
evidence
Both identified studies investigated pharmacological interventions
for the eye movement disorder of nystagmus. Strupp 2003 com-
pared an active pharmacological intervention with an inactive
placebo intervention, while Leigh 1991 was designed as a placebo
control trial but was later determined to compare two different
active pharmacological interventions. It was, therefore, not appro-
priate to combine the results within a meta-analysis.
Both studies had a very small number of participants (total 38)
and there were only a total of five participants with stroke. In the
paper that compared the intervention to placebo (Strupp 2003),
the results within the stroke subgroupwere different to the patients
with other aetiologies. This suggests that these patients may not
respond to the treatment in the same way. This limits the evidence
for the effectiveness of this intervention and its proposed mode of
action in those patients with nystagmus following stroke. There
is, therefore, clearly insufficient evidence from which to draw any
conclusions relating to participants with stroke.
Quality of the evidence
We judged both included studies to have appropriate allocation
concealment and blinding, and assessed neither to have ’other’ po-
tential sources of bias. However, Leigh 1991 reported a high drop-
out rate and we judged that incomplete outcome data were not
addressed adequately. There was insufficient information to judge
whether incomplete outcome data were appropriately addressed
by Strupp 2003.
Potential biases in the review process
Publication bias
Through a thorough searching process we are confident we should
have identified all relevant published studies. However, it must
be acknowledged that there is a possibility that there are addi-
tional studies (published and unpublished) that we did not iden-
tify. Many of the orthoptic journals were not included in the main
databases of research journals covered by our search strategy; how-
ever these were handsearched by one review author (FR).
Categorisation of interventions
We had planned to categorise all interventions as either restitu-
tive, substitutive, compensative or assessment and screening in-
terventions. However, we had not anticipated the identification
of pharmacological interventions when we developed these cate-
gories. We were unable to agree in which of the defined categories
the pharmacological interventions should be included and, after
discussion, we reached consensus that a new category was needed.
As this decision did not alter any subsequent comparison or analy-
sis we do not feel that this introduced bias into the review process.
Studies awaiting classification
We have identified one study (Hofferberth 1995), described as a
controlled trial, which investigates saccadic eyemovement training
in 100 patients with stroke. We have been unable to contact the
study authors to confirm if participants were randomised or not,
although information in the published report suggests that the
control group comprised ’healthy’ participants. If this study is a
RCT then this will contribute a substantial quantity of evidence
to this review.
Muchnick 1998 is a comparison study of surgical interventions for
unilateral superior oblique muscle paresis. There are no data on
the method of allocation nor on the cause of the paresis and thus
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it is not particularly likely to be relevant to this review. We have
been unable to contact the study authors to clarify these issues.
Agreements and disagreements with other
studies or reviews
Th Scottish Intercollegiate Guideline Network (SIGN) guidelines
for stroke rehabilitation state that there is “almost no evidence re-
lating to interventions for eyemovement disorders” and was based
on three reviews (Barrett 2009; Jones 2006; Riggs 2007), each of
which had ’methodological limitations’. Neither the Barrett 2009
nor the Riggs 2007 review identified primary evidence relating to
eyemovement disorders in patients with stroke. Our review agrees
with this finding as to the lack of evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to reach conclusions about the effec-
tiveness of interventions for patients with eyemovement disorders
after stroke.
Implications for research
There is currently an absence of relevant evidence. High-quality
research is, therefore, urgently required.
Are randomised controlled trials required?
Randomised controlled trials (RCTs) are urgently required to de-
termine the effects of clinically relevant rehabilitation interven-
tions and pharmacological interventions in stroke patients com-
pared to no treatment, placebo or usual care.
We recommend that such RCTs must:
1. have adequate power (i.e. with an appropriate power
calculation undertaken based on evidence from phase I and II
studies);
2. have adequate allocation concealment, blinding of outcome
assessor and intention-to-treat analysis;
3. clearly define trial participants; we recommend trials that
include populations with the most common eye movement
disorders of cranial nerve palsies, manifest strabismus, saccadic
palsy and dysmetria, nystagmus and reduced convergence;
4. specifically recruit patients whose eye movement disorders
are due to stroke;
5. include measures of functional ability in activities of daily
living, visual function (including reading measures) and vision-
related quality of life;
6. report clear and usable data.
We recommend that future RCTs concentrate on answering the
specific question relating to the effectiveness of interventions com-
pared with control, placebo, no treatment or usual care rather than
comparisons with variations of the same ’type’ or category of inter-
vention, or comparisons of different doses, adjuncts to treatment
or modes of delivery. We believe that until such time as the ben-
efits of interventions for eye movement disorders compared with
control, placebo, no treatment or usual care have been established
(or refuted) it is not beneficial to compare the relative effects of
different interventions.
Are other primary research studies required?
Other primary research studies may be required in preparation
for well-designed RCTs. In order to predict recruitment rates and
plan future RCTs it would be useful to have clear information
regarding the prevalence of eye-movement disorders within the
stroke population at defined post-stroke time points.
Are further systematic reviews required?
We recommend that systematic reviews of RCTs of interventions
for eyemovement disorders with a neurological cause, but without
a specific stroke aetiology, are carried out. There are a number of
relevant RCTs and such systematic reviews may be used to sup-
port current management for individual patients in the absence
of stroke-specific RCTs. There are already a number of Cochrane
reviews synthesising the evidence from non-stroke populations,
including reviews of botulinum toxin for the treatment of strabis-
mus (Rowe 2009c) and adjustable versus non-adjustable sutures
for strabismus (Haridas 2005).
We recommend systematic reviews of non-randomised studies of
interventions for eye movement disorders in patients with stroke
in order to synthesise the current evidence base, to guide current
practice, and to aid in the development of well-designed RCTs.
Systematic reviews of evidence of the effectiveness of interventions
for specific eye movement disorders in participants with mixed
aetiologiesmay provide evidence which is relevant and transferable
to the population of patients with eye movement disorders as a
result of stroke.
We recommend that this review is updated to identify and include
any further RCTs. We did identify one ongoing study investigat-
ing prismatic spectacle lenses on symptoms of dizziness, headache
and anxiety caused by vertical heterophoria. The researchers have
confirmed that this study does include patients with stroke and it
may therefore be relevant for future updates of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Leigh 1991
Methods Randomised double-blind cross-over trial
Patients “randomly assigned”, no further information available
Participants 10 participants with impaired vision and oscillopsia due to acquired nystagmus
Exclusion criteria: glaucoma, cardiac disease, COPD, bowel disease
The number assigned to each group is not clearly stated.
Method of diagnosing eye movement disorder: presence of oscillopsia, movements of
eye measured using magnetic search coil technique
Interventions Group1:DrugA: trihexyphenidyl 5mg capsules 1 capsule per day.Drugdosage increased
1 tablet per week until taking 4 tablets per day
Group 2: Drug B: tridihexethyl chloride 25 mg 1 capsule per day. Drug dosage increased
1 tablet per week until taking 4 tablets per day
1 to 2-week washout period followed by swap to other tablet
Outcomes Visual Acuity (Snellen)
Nystagmus: horizontal, vertical and torsional movements by magnetic search coil tech-
nique
Notes Only 2 included participants had a stroke - of these only 1 actually took part in the trial,
taking only tridihexethyl chloride
Drug B (tridihexethyl chloride) was meant to be an active control, it is “an anti-cholin-
ergic agent used for the treatment of peptic ulcer ... and ... would not be expected to
cross the blood-brain barrier”. However it was found to produce effects on the outcomes
measured
This was a cross-over trial, with participant changing to the other treatment after 1 to 2
weeks with no treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Randomly assigned”, no further details
Quote “both medications were identical
in appearance”, no further information on
concealment of allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Masking of assessor is not described. How-
ever, participants and assessor should both
be masked as “both medications were iden-
tical in appearance”
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Leigh 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 5 participants completed both Drug
A and Drug B (cross-over phases). 1 partic-
ipant completed Drug A only, 1 completed
Drug B only and 3 completed neither of
the drug interventions
2 participants were unable to tolerate Drug
A, 1 unable to tolerate B, 1 dropped out
afterDrug A asMS relapsed, 1 dropped out
due to unrelated peripheral vascular disease
Other bias Low risk No other potential source of bias noted
Strupp 2003
Methods Prospective randomised controlled double-blind cross-over trial
Method of randomisation: computer-generated randomisation list
Participants 18 participants, 17 randomised
Particpants had down-beat nystagmus, either pure or with co-existent eye movement
problems, but were excluded if they had epilepsy, cardiac arrhythmias, or took drugs that
may affect nervous or vestibular system
Group 1: 8 participants, Group 2: 9 participants; 3/17 had stroke diagnosis (cerebellar
infarction)
Method of diagnosing eye movement disorder: neuro-ophthalmologic and neuro-oto-
logic examination. Electronystagmography and neuro-orthoptic examination (includ-
ing fundus photography and determination of subjective vision)
Interventions Group 1 (pharmacological intervention) 20 mg capsule of 3,4 diaminopyridine (DAP)
and lactose
Group 2 (placebo) lactose capsule
Outcomes Horizontal and vertical eye movements: 2D video-oculography; this was measured 30
minutes after taking the capsule
Questioned as to intensity of oscillopsia (but not recorded)
Side-effect questionnaire 30 and 60 minutes after tablets taken
Notes Cross over study - data analysed as single group
The results of the 3 stroke patients was different to the patients with cerebellar degener-
ation, suggesting that these patients may not respond to the treatment in the same way
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “With use of a computer-generated ran-
domization list, each subject was assigned
by the investigator to initially receive 3,4-
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Strupp 2003 (Continued)
DAP or placebo at least 1 week (washout
period) later. Code envelopes were kept by
the investigator during the trial and re-
turned unopened to the monitor after ter-
mination of the study. The blind was main-
tained until data analysis had been com-
pleted.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “With use of a computer-generated ran-
domization list, each subject was assigned
by the investigator to initially receive 3,4-
DAP or placebo at least 1 week (washout
period) later. Code envelopes were kept by
the investigator during the trial and re-
turned unopened to the monitor after ter-
mination of the study. The blind was main-
tained until data analysis had been com-
pleted.”
“3,4-DAP and placebo. Capsules with 20
mg of 3,4-DAP and lactose or placebo
(a capsule with lactose alone) were man-
ufactured and delivered by the pharmacy
of the University of Munich (Klinikum
Grosshadern). The shape and colour of the
capsules with 3,4-DAP or placebo were
identical. The generic drug for 3,4-DAP
was delivered by Synopharm GmbH Phar-
maceutical Co (Barsbuttel, Germany) to
our pharmacy.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 participant was excluded before start of
intervention due to chronic alcohol abuse
The subjective comments regarding the
severity of oscillopsia not presented
Other bias Low risk No other potential source of bias noted
COPD: chronic obstructive pulmonary disease
MS: multiple sclerosis
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Repka 1989 This study included those with acquired and not congenital esotropia, so could have included those caused by a stroke.
Correspondence with the authors informed us that stroke survivors would not have been eligible to enter their trial,
so this study is not relevant to the review
Characteristics of studies awaiting assessment [ordered by study ID]
Hofferberth 1995
Methods Controlled clinical trial
Participants Ischaemic stroke - 100 trained, 100 not trained (plus 100 normal controls)
Interventions 100 saccadic eye movement training, 100 no treatment
Outcomes Saccadic velocity, number-connection test, spatial orientation
Notes There is no mention of how patients were allocated to treatment groups; attempts to contact the author have so far
yielded no results
Muchnick 1998
Methods Comparison study
Participants 9 patients with Knapp’s class III unilateral superior oblique muscle paresis; aetiology not recorded
Interventions Surgical intervention: 4 had 14 mm recession surgery, 5 had anterior transposition of the superior oblique muscle
Outcomes Magnitude of deviation in the primary position and 8 cardinal positions of gaze
Notes There is no mention of how patients were allocated to treatment groups; attempts to contact the author have so far
yielded no results
Characteristics of ongoing studies [ordered by study ID]
Rosner 2010
Trial name or title Effects of prismatic spectacle lenses on symptoms of dizziness, headache and anxiety as caused by vertical
heterophoria
Methods Randomised, double-blind cross-over study
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Rosner 2010 (Continued)
Participants Symptoms of dizziness and/or headache lasting longer than 4 months and diagnosed with a vertical het-
erophoria
Interventions Intervention: lenses containing prismatic correction
Placebo: lenses not containing prismatic correction
Outcomes Symptomatology self-survey tools
Starting date November 2008
Contact information Mark S Rosner, MD msr50@comcast.net
Notes Due to finish December 2010
Correspondence with the author confirms that a number of the participants’ phorias are as a consequence of
stroke
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Demographics of included studies: settings of included studies
Study Leigh 1991 Strupp 2003
Country USA Germany
Setting for Intervention Not stated Outpatient clinic
Table 2. Demographics of included studies: demographics of included participants
Study Leigh 1991 Strupp 2003
No. of participants 10 17
Age Range 23 to 82 years
Mean 46.1
SD 18.14
50 to 85 years
Mean 67.64
SD 9.92
Gender 5 female
5 male
8 female
9 male
Time since stroke/lesion Not stated Of infarct (3 patients)
Range 6 to 36 months
Initial functional ability Not stated Not stated
Type of stroke/lesion 1 post-surgical hypoxia
2 infarction
6 MS
1 cerebellar degeneration
Cerebellar atrophy 5
Infarction 3
Arnold-Chiari Malformation 1
Unknown 8
Side of stroke/lesion Not stated Of infarct
R 2
Midline 1
MS: multiple
SD: standard deviation
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Table 3. Demographics of included studies: disorders of eye movements
Study Leigh 1991 Strupp 2003
Type of eye movement disorder Nystagmus Downbeat nystagmus
Deviation of eye movement
(horizontal, vertical, torsional)
1 seesaw
2 torsional
2 downbeat
5 pendular/elliptical
Downbeat
Severity of eye movement disorder
(slight/small/moderate/severe)(paralysis/
paresis) (monocular/binocular)
Not stated Not stated
NB: variety of additional eye movement
disorders including rebound nystagmus (N
= 6), hypermetric saccades (N = 2) and
fourth nerve palsy (N = 1)
Age-related eye problems? Yes/No Not stated
(glaucoma is an exclusion criterion)
Not stated
Visual field impairment? Yes/No No Not stated
Visual inattention? Yes/No No No
Level of motor impairment (mild/mod-
erate/severe)
Not stated Not stated
Level of cognitive impairment (mild/
moderate/severe)
Not stated Not stated
A P P E N D I C E S
Appendix 1. CENTRAL (The Cochrane Library) search strategy
To avoid duplication of effort we designed broad search strategies for the major databases sensitive enough to cover the scope of a series
of three Cochrane reviews of interventions for different visual disorders following stroke.We devised the following search strategy, using
a combination of controlled vocabulary (MeSH) and free text terms, forMEDLINE andmodified it to suit other databases: MEDLINE
(Appendix 2); EMBASE (Ovid) (Appendix 3); CINAHL (EBSCO) (Appendix 4); AMED (Ovid) (Appendix 5); PsycINFO (Ovid)
(Appendix 6).
1. MeSH descriptor Cerebrovascular Disorders, this term only
2. MeSH descriptor Basal Ganglia Cerebrovascular Disease explode all trees
3. MeSH descriptor Brain Ischemia explode all trees
4. MeSH descriptor Carotid Artery Diseases explode all trees
5. MeSH descriptor Intracranial Arterial Diseases explode all trees
6. MeSH descriptor Intracranial Arteriovenous Malformations explode all trees
7. MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
22Interventions for disorders of eye movement in patients with stroke (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8. MeSH descriptor Intracranial Hemorrhages explode all trees
9. MeSH descriptor Stroke explode all trees
10. MeSH descriptor Brain Infarction explode all trees
11. MeSH descriptor Vasospasm, Intracranial, this term only
12. MeSH descriptor Vertebral Artery Dissection, this term only
13. stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH
14. (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*)
15. (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)
16. MeSH descriptor Hemiplegia, this term only
17. MeSH descriptor Paresis explode all trees
18. hemipleg* or hemipar* or paresis or paretic 1735
19. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18)
20. MeSH descriptor Eye explode all trees
21. MeSH descriptor Visually Impaired Persons explode all trees
22. MeSH descriptor Ocular Physiological Processes explode all trees
23. MeSH descriptor Diagnostic Techniques, Ophthalmological explode all trees
24. MeSH descriptor Optometry explode all trees
25. MeSH descriptor Orthoptics explode all trees
26. MeSH descriptor Eye Diseases, this term only
27. MeSH descriptor Vision Disorders, this term only
28. MeSH descriptor Eye Manifestations, this term only
29. MeSH descriptor Blindness, this term only
30. MeSH descriptor Diplopia explode all trees
31. MeSH descriptor Vision, Binocular, this term only
32. MeSH descriptor Vision, Monocular, this term only
33. MeSH descriptor Visual Acuity explode all trees
34. MeSH descriptor Visual Fields, this term only
35. MeSH descriptor Vision, Low, this term only
36. MeSH descriptor Perimetry, this term only
37. MeSH descriptor Ophthalmology, this term only
38. MeSH descriptor Vision Screening, this term only
39. MeSH descriptor Eye Diseases, Hereditary explode all trees
40. MeSH descriptor Eye Hemorrhage explode all trees
41. MeSH descriptor Lacrimal Apparatus Diseases explode all trees
42. MeSH descriptor Lens Diseases explode all trees
43. MeSH descriptor Ocular Hypertension explode all trees
44. MeSH descriptor Ocular Hypotension explode all trees
45. MeSH descriptor Ocular Motility Disorders explode all trees
46. MeSH descriptor Optic Nerve Diseases explode all trees
47. MeSH descriptor Orbital Diseases explode all trees
48. MeSH descriptor Pupil Disorders explode all trees
49. MeSH descriptor Refractive Errors explode all trees
50. MeSH descriptor Retinal Diseases explode all trees
51. MeSH descriptor Blindness, Cortical explode all trees
52. MeSH descriptor Hemianopsia explode all trees
53. MeSH descriptor Vitreoretinopathy, Proliferative explode all trees
54. MeSH descriptor Vitreous Detachment explode all trees
55. MeSH descriptor Scotoma, this term only
56. MeSH descriptor Abducens Nerve, this term only
57. MeSH descriptor Oculomotor Nerve, this term only
58. MeSH descriptor Trochlear Nerve, this term only
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59. nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder* or retinal or retinopathy or macular
degeneration or glaucoma or cataract* or ophthalmol* or optic nerve
60. intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
61. one near/3 half syndrome
62. (visual* or vision or eye or eyes or eyesight or sight) near/5 (problem* or disorder* or impair* or disabilit* or loss or disease* or
defect* or manifestation* or screening or test* or examination*)
63. hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr* or ocular or orthoptic*
64. oscillopsia or visual tracking or fresnel prism*
65. III or IV or VI or third or fourth or sixth near/3 nerve palsy
66. (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #
34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #
49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #
64 OR #65)
67. (#19 AND #66)
68. MeSH descriptor Infant explode all trees
69. MeSH descriptor Child explode all trees
70. neonat* or child or children or childhood or juvenile or infan* or toddler
71. MeSH descriptor Neoplasms explode all trees
72. cancer* or carcinoma* or tumor* or tumour* or neoplasm*
73. (#68 OR #69 OR #70 OR #71 OR #72)
74. (#67 AND NOT #73)
Appendix 2. MEDLINE (Ovid) search strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp “intracranial embolism and thrombosis”/ or exp
intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. exp visually impaired persons/
10. exp ocular physiological processes/ or exp diagnostic techniques, ophthalmological/
11. Optometry/ or Orthoptics/
12. eye diseases/ or vision disorders/ or eye manifestations/ or blindness/ or diplopia/
13. vision, binocular/ or vision, monocular/ or exp visual acuity/ or visual fields/ or vision, low/ or perimetry/ or ophthalmology/ or
vision screening/
14. exp eye diseases, hereditary/ or exp eye hemorrhage/ or exp lacrimal apparatus diseases/ or exp lens diseases/ or exp ocular
hypertension/ or exp ocular hypotension/ or exp ocular motility disorders/ or exp optic nerve diseases/ or exp orbital diseases/ or exp
pupil disorders/ or exp refractive errors/ or exp retinal diseases/ or exp blindness, cortical/ or exp hemianopsia/ or exp vitreoretinopathy,
proliferative/ or exp vitreous detachment/ or scotoma/
15. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
16. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or retinal or retinopathy or macular
degeneration or glaucoma or cataract$ or ophthalmol$ or optic nerve).tw.
17. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw
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18. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
19. (hemianop$ or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr$ or ocular or orthoptic$).tw.
20. (oscillopsia or visual tracking or fresnel prism$).tw
21. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw
22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. 7 and 22
24. Randomized Controlled Trials as Topic/
25. random allocation/
26. Controlled Clinical Trials as Topic/
27. control groups/
28. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
29. double-blind method/
30. single-blind method/
31. Placebos/
32. placebo effect/
33. cross-over studies/
34. Multicenter Studies as Topic/
35. Therapies, Investigational/
36. Drug Evaluation/
37. Research Design/
38. Program Evaluation/
39. evaluation studies as topic/
40. randomized controlled trial.pt.
41. controlled clinical trial.pt.
42. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
43. multicenter study.pt.
44. (evaluation studies or comparative study).pt.
45. random$.tw.
46. (controlled adj5 (trial$ or stud$)).tw.
47. (clinical$ adj5 trial$).tw.
48. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
49. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
50. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
51. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
52. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
53. (coin adj5 (flip or flipped or toss$)).tw.
54. latin square.tw.
55. versus.tw.
56. (cross-over or cross over or crossover).tw.
57. placebo$.tw.
58. sham.tw.
59. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
60. controls.tw.
61. (treatment$ adj6 order).tw.
62. or/24-61
63. 23 and 62
64. exp child/ or exp infant/
65. (neonat$ or child or children or childhood or juvenile or infant or toddler).tw
66. exp neoplasms/
67. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw
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68. case reports.pt or case report$.tw
69. 64 or 65 or 66 or 67 or 68
70. 63 not 69
71. limit 70 to humans
Appendix 3. EMBASE search strategy
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or exp carotid
artery disease/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp cerebrovascular
malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or stroke unit/ or stroke patient.mp. [mp=title,
abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/ or paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/ or exp eye disease/ or exp visual disorder/
9. exp visual system examination/ or eye examination/ or exp vision test/
10. exp ophthalmology/ or orthoptics/ or exp visual system/ or exp visual system function/ or depth perception/
11. exp visual aid/
12. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
13. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or retinal or retinopathy or macular
degeneration or glaucoma or cataract$ or ophthalmol$ or optic nerve).tw.
14. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
15. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
16. (hemianop$ or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr$ or ocular or orthoptic$).tw.
17. (oscillopsia or visual tracking or fresnel prism$).tw.
18. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 7 and 19
21. Randomized Controlled Trial/
22. Randomization/
23. Controlled Study/
24. control group/
25. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical
trial/
26. Crossover Procedure/
27. Double Blind Procedure/
28. Single Blind Procedure/ or triple blind procedure/
29. latin square design/
30. Parallel Design/
31. placebo/
32. Multicenter Study/
33. experimental design/ or experimental study/ or quasi experimental study/
34. experimental therapy/
35. drug comparison/ or drug dose comparison/
36. drug screening/
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37. Evaluation/ or “Evaluation and Follow Up”/ or evaluation research/ or clinical evaluation/
38. Methodology/
39. “types of study”/
40. research subject/
41. Comparative Study/
42. random$.tw.
43. (controlled adj5 (trial$ or stud$)).tw.
44. (clinical$ adj5 trial$).tw.
45. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
46. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
47. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
48. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
49. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
50. (coin adj5 (flip or flipped or toss$)).tw.
51. latin square.tw.
52. versus.tw.
53. (cross-over or cross over or crossover).tw.
54. placebo$.tw.
55. sham.tw.
56. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
57. controls.tw.
58. (treatment$ adj6 order).tw.
59. or/21-58
60. 20 and 59
61. exp child/ or exp newborn/
62. (neonat$ or child or children or childhood or juvenile or infant or toddler).tw.
63. exp Neoplasm/
64. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw.
65. case report/ or case study/
66. 61 or 62 or 63 or 64 or 65
67. 60 not 66
68. limit 67 to human
Appendix 4. CINAHL search strategy
1. MH “Cerebrovascular Disorders+” or MH “stroke patients” or MH “stroke units”
2. TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* ) or AB ( stroke or poststroke or post-stroke or cerebrovasc*
or brain vasc* )
3. TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or intracerebral
)
4. TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or thrombo* or
emboli* or occlus* )
5. S3 and S4
6. TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachmoid ) or AB ( brain* or cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid )
7. TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed* )
8. S6 and S7
9. MH “Hemiplegia”
10. TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic
11. S1 or S2 or S5 or S8 or S9 or S10
12. MH “Eye+” or MH “Rehabilitation of Vision Impaired+” or MH “Optometry” or MH “Eye Diseases+”
27Interventions for disorders of eye movement in patients with stroke (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13. MH “Visual Acuity+” or MH “Perimetry+” or MH “Ophthalmology+” or MH “Vision Screening+” or MH “Ocular Physiology+”
14. TI ( orthoptics or vision, monocular or vision, binocular ) or AB ( orthoptics or vision, monocular or vision, binocular )
15. TI ( vitreous detachment or hemianopsia or hemianopia or quadrantanopia ) or AB ( vitreous detachment or hemianopsia or
hemianopia or quadrantanopia )
16. MH “Abducens Nerve” or MH “oculomotor nerve” or MH “troclear nerve” or MH “optic nerve” or MH “nystagmus, pathologic
17. TI ( smooth pursuit or saccades or gaze disorder* or retinal or retinopathy or ophthalmol* ) or AB ( smooth pursuit or saccades or
gaze disorder* or retinal or retinopathy or ophthalmol*)
18. TI ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometry* or ocular or orthoptic* ) or AB ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous
detachment or scotoma or diplopia or optometry* or ocular or orthoptic* )
19. TI ( oscillopsia or visual tracking or fresnel prism* ) or AB ( oscillopsia or visual tracking or fresnel prism* )
20. TI ( intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation ) or AB (
intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation )
21. TI ( visual* or vision or eye or eyes or eyesight or sight ) or AB ( visual* or vision or eye or eyes or eyesight or sight )
22. TI ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or test* or
examination* ) or AB ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or
test* or examination* )
23. 21 and S22
24. TI ( third or fourth or sixth ) or AB ( third or fourth or sixth )
25. AB nerve palsy or TI nerve palsy
26. S24 and S25
27. S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S23 or S26
28. S11 and S27
29. (MH ”Random Assignment“) or (MH ”Random Sample+“)
30. (MH ”Crossover Design“) or (MH ”Clinical Trials+“) or (MH ”Comparative Studies“)
31. (MH ”Control (Research)“) or (MH ”Control Group“)
32.(MH ”Factorial Design“) or (MH ”Quasi-Experimental Studies“) or (MH ”Nonrandomized Trials“)
33. (MH ”Placebo Effect“) or (MH ”Placebos“) or (MH ”Meta Analysis“)
34. (MH ”Community Trials“) or (MH ”Experimental Studies“) or (MH ”One-Shot Case Study“) or (MH ”Pretest-Posttest Design+“)
or (MH ”Solomon Four-Group Design“) or (MH ”Static Group Comparison“)
or (MH ”Study Design“)
35. (MH ”Clinical Research“) or (MH ”Clinical Nursing Research“)
36. PT clinical trial
37. PT systematic review
38. TI random* or AB random*
39. TI ( singl* or doubl* or tripl* or trebl* ) or AB ( singl* or doubl* or tripl* or trebl* )
40. TI ( blind* or mask* ) or AB ( blind* or mask*)
41. S39 and S40
42. TI ( crossover or cross-over or placebo* or control* or factorial or sham ) or AB ( crossover or cross-over or placebo* or control* or
factorial or sham )
43. TI ( clin* or intervention* or compar* or experiment* or preventive or therapeutic ) or AB ( clin* or intervention* or compar* or
experiment* or preventive or therapeutic )
44. TI trial* or AB trial*
45. S43 and S44
46. TI ( counterbalance* or multiple baseline* or ABAB design ) or AB ( counterbalance* or multiple baseline* or ABAB design )
47. TI ( meta analysis* or metaanlaysis or meta-anlaysis or systematic review* ) or AB ( meta analysis* or metaanlaysis or meta-anlaysis
or systematic review* )
48. S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S41 or S42 or S45 or S46 or S47
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Appendix 5. AMED search strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp ”intracranial embolism and thrombosis“/ or exp
intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. exp visually impaired persons/
10. exp ocular physiological processes/ or exp diagnostic techniques, ophthalmological/
11. Optometry/ or Orthoptics/
12. eye diseases/ or vision disorders/ or eye manifestations/ or blindness/ or diplopia/
13. vision, binocular/ or vision, monocular/ or exp visual acuity/ or visual fields/ or vision, low/ or perimetry/ or ophthalmology/ or
vision screening/
14. exp eye diseases, hereditary/ or exp eye hemorrhage/ or exp lacrimal apparatus diseases/ or exp lens diseases/ or exp ocular
hypertension/ or exp ocular hypotension/ or exp ocular motility disorders/ or exp optic nerve diseases/ or exp orbital diseases/ or exp
pupil disorders/ or exp refractive errors/ or exp retinal diseases/ or exp blindness, cortical/ or exp hemianopsia/ or exp vitreoretinopathy,
proliferative/ or exp vitreous detachment/ or scotoma/
15. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
16. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or retinal or retinopathy or macular
degeneration or glaucoma or cataract$ or ophthalmol$ or optic nerve).tw.
17. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw
18. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
19. (hemianop$ or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr$ or ocular or orthoptic$).tw.
20. (oscillopsia or visual tracking or fresnel prism$).tw
21. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw
22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. 7 and 22
24. Randomized Controlled Trials as Topic/
25. random allocation/
26. Controlled Clinical Trials as Topic/
27. control groups/
28. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
29. double-blind method/
30. single-blind method/
31. Placebos/
32. placebo effect/
33. cross-over studies/
34. Multicenter Studies as Topic/
35. Therapies, Investigational/
36. Drug Evaluation/
37. Research Design/
38. Program Evaluation/
39. evaluation studies as topic/
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40. randomized controlled trial.pt.
41. controlled clinical trial.pt.
42. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
43. multicenter study.pt.
44. (evaluation studies or comparative study).pt.
45. random$.tw.
46. (controlled adj5 (trial$ or stud$)).tw.
47. (clinical$ adj5 trial$).tw.
48. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
49. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
50. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
51. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
52. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
53. (coin adj5 (flip or flipped or toss$)).tw.
54. latin square.tw.
55. versus.tw.
56. (cross-over or cross over or crossover).tw.
57. placebo$.tw.
58. sham.tw.
59. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
60. controls.tw.
61. (treatment$ adj6 order).tw.
62. or/24-61
63. 23 and 62
64. exp child/ or exp infant/
65. (neonat$ or child or children or childhood or juvenile or infant or toddler).tw
66. exp neoplasms/
67. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw
68. case reports.pt or case report$.tw
69. 64 or 65 or 66 or 67 or 68
70. 63 not 69
71. limit 70 to humans
Appendix 6. PsycINFO search strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp ”intracranial embolism and thrombosis“/ or exp
intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. exp visually impaired persons/
10. exp ocular physiological processes/ or exp diagnostic techniques, ophthalmological/
11. Optometry/ or Orthoptics/
12. eye diseases/ or vision disorders/ or eye manifestations/ or blindness/ or diplopia/
13. vision, binocular/ or vision, monocular/ or exp visual acuity/ or visual fields/ or vision, low/ or perimetry/ or ophthalmology/ or
vision screening/
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14. exp eye diseases, hereditary/ or exp eye hemorrhage/ or exp lacrimal apparatus diseases/ or exp lens diseases/ or exp ocular
hypertension/ or exp ocular hypotension/ or exp ocular motility disorders/ or exp optic nerve diseases/ or exp orbital diseases/ or exp
pupil disorders/ or exp refractive errors/ or exp retinal diseases/ or exp blindness, cortical/ or exp hemianopsia/ or exp vitreoretinopathy,
proliferative/ or exp vitreous detachment/ or scotoma/
15. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
16. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or retinal or retinopathy or macular
degeneration or glaucoma or cataract$ or ophthalmol$ or optic nerve).tw.
17. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw
18. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
19. (hemianop$ or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr$ or ocular or orthoptic$).tw.
20. (oscillopsia or visual tracking or fresnel prism$).tw
21. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw
22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. 7 and 22
24. Randomized Controlled Trials as Topic/
25. random allocation/
26. Controlled Clinical Trials as Topic/
27. control groups/
28. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
29. double-blind method/
30. single-blind method/
31. Placebos/
32. placebo effect/
33. cross-over studies/
34. Multicenter Studies as Topic/
35. Therapies, Investigational/
36. Drug Evaluation/
37. Research Design/
38. Program Evaluation/
39. evaluation studies as topic/
40. randomized controlled trial.pt.
41. controlled clinical trial.pt.
42. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
43. multicenter study.pt.
44. (evaluation studies or comparative study).pt.
45. random$.tw.
46. (controlled adj5 (trial$ or stud$)).tw.
47. (clinical$ adj5 trial$).tw.
48. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
49. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
50. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
51. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
52. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
53. (coin adj5 (flip or flipped or toss$)).tw.
54. latin square.tw.
55. versus.tw.
56. (cross-over or cross over or crossover).tw.
57. placebo$.tw.
58. sham.tw.
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59. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
60. controls.tw.
61. (treatment$ adj6 order).tw.
62. or/24-61
63. 23 and 62
64. exp child/ or exp infant/
65. (neonat$ or child or children or childhood or juvenile or infant or toddler).tw
66. exp neoplasms/
67. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw
68. case reports.pt or case report$.tw
69. 64 or 65 or 66 or 67 or 68
70. 63 not 69
71. limit 70 to humans
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